Novan Presents Safety Data for SB204 Program
No Detectable Systemic Exposure in Three Pharmacokinetic Clinical Trials
Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic data for SB204, a once-daily, topical monotherapy for the treatment of acne vulgaris, will be presented at the 76th Annual Meeting of the Society for Investigative Dermatology in Portland, Oregon. In three pharmacokinetic clinical trials conducted in patients with moderate to severe acne to assess systemic exposure following topical application of SB204, there was no detectable systemic exposure to markers for nitric oxide exposure in adults or adolescents treated with SB204 under maximal use conditions. Maximal use conditions were defined as application of SB204 Gel or vehicle to 17% of body surface area, or the face, upper chest, upper back and shoulders, of patients with moderate to severe acne. In general, all doses of SB204 were well tolerated and not associated with any significant safety issues in these trials.